These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Reducing the risk for suicide in schizophrenia and affective disorders. Meltzer HY; Baldessarini RJ J Clin Psychiatry; 2003 Sep; 64(9):1122-9. PubMed ID: 14628990 [No Abstract] [Full Text] [Related]
13. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413 [TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez JC; Crawford AM J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753 [TBL] [Abstract][Full Text] [Related]
15. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Kopelowicz A; Zarate R; Tripodis K; Gonzalez V; Mintz J Am J Psychiatry; 2000 Jun; 157(6):987-93. PubMed ID: 10831481 [TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Conley RR; Mahmoud R Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400 [TBL] [Abstract][Full Text] [Related]
17. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia]. Radziwiłłowicz P; Radziwiłłowicz W; Lis J Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025 [TBL] [Abstract][Full Text] [Related]
18. Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. Gray R Ment Health Care; 1998 Feb; 1(6):193-4. PubMed ID: 9791411 [TBL] [Abstract][Full Text] [Related]
19. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients]. Briken P; Nika E; Krausz M; Naber D Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946 [TBL] [Abstract][Full Text] [Related]
20. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson GD; Sanger TM Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]